Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2 | P00734 | 8/20 | 0.71 |
| ▸ | PRSS1 | P07477 | 2/20 | 0.71 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.71 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.71 |
| ▸ | TMPRSS6 | Q8IU80 | 1/20 | 0.71 |
| ▸ | ST14 | Q9Y5Y6 | 1/20 | 0.71 |
| ▸ | PLAU | P00749 | 7/20 | 0.50 |
| ▸ | F10 | P00742 | 6/20 | 0.50 |
| ▸ | PLAT | P00750 | 6/20 | 0.50 |
| ▸ | PLG | P00747 | 5/20 | 0.50 |
| ▸ | KLK1 | P06870 | 2/20 | 0.47 |
| ▸ | KLK5 | Q9Y337 | 2/20 | 0.47 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.44 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.44 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20118775 | 0.84 | F2 (0.63) | F2PRSS1PRSS2PRSS3TMPRSS6 | |
| SCHEMBL13464634 | 0.82 | NPC1 (0.55) | — | |
| SCHEMBL2135316 | 0.81 | F2 (0.73) | F2PRSS1PRSS2PRSS3TMPRSS6 | |
| SCHEMBL7903320 | 0.80 | F2 (0.71) | F2PRSS1PRSS2PRSS3TMPRSS6 | |
| Hydrochloric Acid SCHEMBL29246859 | 0.79 | F2 (0.69) | F2PRSS1PRSS2PRSS3TMPRSS6 | |
| SCHEMBL20118485 | 0.78 | F2 (0.54) | F2PRSS1PRSS2PRSS3TMPRSS6 | |
| SCHEMBL28716771 | 0.77 | TDP1 (0.61) | — | |
| SCHEMBL20115291 | 0.77 | SMN1; SMN2 (0.42) | — | |
| SCHEMBL4553738 | 0.76 | F2 (0.77) | F2PRSS1PRSS2PRSS3TMPRSS6 | |
| SCHEMBL20118279 | 0.76 | L3MBTL1 (0.45) | F2PRSS1PRSS2PRSS3TMPRSS6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3532057-B1 | PRODRUGS OF KALLIKREIN INHIBITORS | BIOCRYST PHARM INC (US) | 2022-12-21 | — | — | EP | disclosed |
| US-10759759-B2 | Prodrugs of kallikrein inhibitors | BIOCRYST PHARMACEUTICALS, INC. (US) | 2020-09-01 | — | — | US | disclosed |
| WO-2018081513-A1 | PRODRUGS OF KALLIKREIN INHIBITORS | BIOCRYST PHARMACEUTICALS, INC. (US) | 2018-05-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10759759-B2 | Prodrugs of kallikrein inhibitors | KLKB1, SERPINB1, KLK1 | F2 85/4885PRSS1 38/4885PRSS2 94/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.